226 filings
Page 2 of 12
S-8 POS
d8s mt3tj26
28 Mar 23
Registration of securities for employees (post-effective amendment)
4:30pm
25
3dy14wk
27 Mar 23
Voluntary exchange delisting
4:20pm
8-K
2rlc bkstku
22 Mar 23
Other Events
5:23pm
8-K
to6f23nrnyaygkr
15 Mar 23
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
7:30am
8-K
xm4f7u4 zguwy
13 Mar 23
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
7:05am
8-K
9iexyuv 7hxj12ovvu
1 Mar 23
Entry into a Material Definitive Agreement
8:30am
8-K
s4odmqhu
24 Feb 23
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
9:26am
8-K
95u vbljb4i1j0jysq
3 Jan 23
Regulation FD Disclosure
8:00am
6-K
ztnxvbg
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
6-K
i8g5ypnj3g yo9a8kyyi
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
EFFECT
xlkow uu0nuxepjljii2
13 Dec 22
Notice of effectiveness
12:15am
6-K
n65frx8ck4u6 n8
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
F-3
d2xq9
9 Dec 22
Shelf registration (foreign)
7:06am
UPLOAD
ol2rm t1w
9 Dec 22
Letter from SEC
12:00am
CORRESP
jp4hlsya8h1a6
9 Dec 22
Correspondence with SEC
12:00am
6-K
2x8k6fu
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
rv88u3wmwpnjy1aa9ax
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
b1xg6n5rz9spwf410t
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
oseu6x 07
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
1azgb xyigkwc0i
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am